Proxy Votes Now

Home › Funds › BlackRock › iShares Health Innovation Active ETF

iShares Health Innovation Active ETF proxy voting record 2025-2026

Fund family: BlackRock · Filed by BlackRock ETF Trust (CIK 1761055) · SEC series S000069260

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 595 with, 13 against, 8 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 1 FOR, 12 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with BlackRock as a whole

The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsBlackRockItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)97.3%55393.6%1,355,861
Backed environmental and social shareholder proposals at US companiesn/a25.5%6,306

Where this fund voted differently from most BlackRock funds

Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most BlackRock funds on 18 items (3.1% of the 585 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost BlackRock fundsMgmtResult
ROIVANT SCIENCES LTD.2025-09-10To cast a non-binding, advisory vote to approve the compensation of our named executive officers.ForAGAINST — 32 of 35 BlackRock fundsForApproved, 60.9% support
BIO-TECHNE CORP2025-10-30Approve, on an advisory basis, the compensation of our executive officers.AgainstFOR — 35 of 42 BlackRock fundsAgainstApproved, 72.1% support
HOLOGIC, INC.2026-02-05A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger.ForAGAINST — 50 of 64 BlackRock fundsFor—
INCYTE CORPORATION2026-06-08Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 54 of 73 BlackRock fundsForApproved, 83.9% support
EXACT SCIENCES CORPORATION2026-02-20Proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Exact Sciences Corporation's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by the Merger Agreement (the "CompensatForAGAINST — 31 of 40 BlackRock fundsFor—
WUXI BIOLOGICS (CAYMAN) INC.2026-06-10Approve Deloitte Touche Tohmatsu as Auditors and Authorize the Board of Directors or Any Duly Authorized Board Committee to Fix Their RemunerationAgainstFOR — 13 of 15 BlackRock fundsAgainst—
WUXI BIOLOGICS (CAYMAN) INC.2026-06-10Elect Ge Li as DirectorAgainstFOR — 13 of 15 BlackRock fundsAgainst—
INCYTE CORPORATION2026-06-08Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques BienaiméForAGAINST — 44 of 60 BlackRock fundsFor—
WAVE LIFE SCIENCES LTD.2025-08-05To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.AgainstFOR — 14 of 17 BlackRock fundsAgainstApproved, 78.2% support
SUMMIT THERAPEUTICS INC.2026-06-10Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock.ForAGAINST — 14 of 18 BlackRock fundsForPassed (calculated), 95.8% support
SUMMIT THERAPEUTICS INC.2026-06-10DIRECTOR: Kenneth A. ClarkForABSTAIN — 14 of 18 BlackRock fundsFor—
AVIDITY BIOSCIENCES, INC.2026-02-26To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.ForAGAINST — 23 of 34 BlackRock fundsForApproved, 82.4% support
PROTAGONIST THERAPEUTICS, INC.2026-06-17DIRECTOR: L.T. Williams, MD, PhDAbstainFOR — 19 of 28 BlackRock fundsAgainst—
BRIGHT MINDS BIOSCIENCES INC.2026-03-31DIRECTOR: David WeinerAbstainFOR — 8 of 10 BlackRock fundsAgainst—
BRIGHT MINDS BIOSCIENCES INC.2026-03-31DIRECTOR: Jan PedersenAbstainFOR — 8 of 10 BlackRock fundsAgainst—
BRIGHT MINDS BIOSCIENCES INC.2026-03-31DIRECTOR: Jeremy FryzukAbstainFOR — 8 of 10 BlackRock fundsAgainst—
MODERNA, INC.2026-05-06To approve, on a non-binding, advisory basis, the compensation of our named executive officers.AgainstFOR — 33 of 59 BlackRock fundsAgainstApproved, 65.1% support
MERUS N.V.2025-12-09Non-binding advisory proposal to approve certain compensation arrangementsForAGAINST — 12 of 19 BlackRock fundsForPassed (calculated), 55.9% support

Download all 18 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 71.4% of this fund’s 616 such votes could be given a sector; the other 176 (28.6%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care384123.1%
Industrials5611.8%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections3920
Say-on-Pay540
Audit-related510
Corporate Governance508
Capital Structure270
Compensation250
Shareholder Rights and Defenses93
Extraordinary Transactions80
Other Social Issues62

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
MERCK & CO., INC.May 26, 2026$696,586183
JOHNSON & JOHNSONApril 23, 2026$679,382151
AMGEN INC.May 19, 2026$607,951151
EDWARDS LIFESCIENCES CORPORATIONMay 7, 2026$600,459120
CHARLES RIVER LABORATORIES INTL., INC.May 5, 2026$587,390150
BIOGEN INC.June 9, 2026$486,943120
WATERS CORPORATIONMay 21, 2026$460,771130
INTUITIVE SURGICAL, INC.April 30, 2026$436,437130

Notable votes against management

MeetingCompanyProposalFundMgmt
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 23, 2026JOHNSON & JOHNSONIndependent Board Chair Shareholder proposalAgainstFor
May 19, 2026AMGEN INC.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026VERTEX PHARMACEUTICALS INCORPORATEDShareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
May 12, 2026IDEXX LABORATORIES, INC.Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). Shareholder proposalAgainstFor
April 23, 2026IQVIA HOLDINGS INC.If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposalAgainstFor
April 21, 2026BIO-RAD LABORATORIES, INC.Stockholder proposal regarding dual class capital structure. Shareholder proposalForAgainst
April 23, 2026PFIZER INC.Adopt an Independent Chair Policy Shareholder proposalAgainstFor

Search this fund’s votes by company

622 ballot items at 59 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, iShares Health Innovation Active ETF voted at 59 shareholder meetings of 57 companies, on 622 ballot items in all. Where management made a recommendation, the fund followed it on 96.6% of the items and voted against it 13 times. Its most frequent area of disagreement was corporate governance (8 of its votes against management). It voted on 13 shareholder proposals. It voted FOR the board's own proposals more often than BlackRock's funds as a whole (97.3% against 93.6%). It voted differently from most BlackRock funds on 18 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.